SG135193A1 - Dosing schedule for erbb2 anticancer agents - Google Patents

Dosing schedule for erbb2 anticancer agents

Info

Publication number
SG135193A1
SG135193A1 SG200706063-5A SG2007060635A SG135193A1 SG 135193 A1 SG135193 A1 SG 135193A1 SG 2007060635 A SG2007060635 A SG 2007060635A SG 135193 A1 SG135193 A1 SG 135193A1
Authority
SG
Singapore
Prior art keywords
erbb2
mammal
directed
inhibitor
anticancer agents
Prior art date
Application number
SG200706063-5A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SG135193A1 publication Critical patent/SG135193A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200706063-5A 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents SG135193A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
SG135193A1 true SG135193A1 (en) 2007-09-28

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200706063-5A SG135193A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20060037447A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US8318752B2 (en) 2003-09-19 2012-11-27 Astrazeneca Ab 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
AU2006259261B2 (en) * 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
EP2004165A2 (en) * 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
AU2007319825B2 (en) 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
WO2013078440A2 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CN110564604B (zh) * 2014-01-31 2023-09-29 凸版印刷株式会社 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
WO2003049740A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
HRP20040530A2 (en) * 2001-12-12 2004-10-31 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
EP1658080A1 (en) 2006-05-24
WO2005016347A1 (en) 2005-02-24
KR20060037447A (ko) 2006-05-03
KR20080014144A (ko) 2008-02-13
NO20061252L (no) 2006-05-16
AR045268A1 (es) 2005-10-19
RU2328287C2 (ru) 2008-07-10
CN1838959A (zh) 2006-09-27
BRPI0413745A (pt) 2006-10-24
CA2536140A1 (en) 2005-02-24
AU2004264726A1 (en) 2005-02-24
TW200522966A (en) 2005-07-16
JP2007502807A (ja) 2007-02-15
IL173127A0 (en) 2006-06-11
MXPA06001989A (es) 2006-05-17
ZA200600517B (en) 2007-02-28
CO5670356A2 (es) 2006-08-31
US20050119288A1 (en) 2005-06-02
RU2006102125A (ru) 2007-09-27

Similar Documents

Publication Publication Date Title
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
JOP20240084A1 (ar) مركبات الكينولين كمثبطات لـ kras
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
AU2483000A (en) Treatment of asthma with mek inhibitors
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
TW200806299A (en) Treatment of pain
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
SI1530469T1 (sl) Transdermalna odmerna oblika, ki obsega aktivno sredstvo in antagonist v obliki soli in v obliki proste baze
MY125490A (en) Method of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200639159A (en) Treatment of pain
CA2235412A1 (en) Pharmaceutical composition containing an activin or inhibin stimulator
IL165259A (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
WO2005077082A3 (en) INHIBITING CAV3 ISOFORMS AND THE δ25B SPLICE VARIENTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
ZA202104960B (en) Methods of treating pain with a thiazoline anti-hyperalgesic